Clinical Trial Update: Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt [Phase 4]

View source ↗

Summary

A Phase 4 trial update evaluating the clinical and pharmacoeconomic aspects of CDK4/6 inhibitors in breast cancer in Egypt.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)
• KISQALI (ribociclib)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Beni-Suef University | Conditions: Breast Cancer | Phase 4 | Status: COMPLETED